1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the stituto Nazionale dei Tumori hospital in Milan, Italy. There it was used for the treatment of a patient suffering from hepatocellular carcinoma (HCC). QuiremSpheres® are radioactive microspheres for SIRT and are based on the isotope holmium-166. 

Voor meer informatie: http://www.quirem.com/

1st production QuiremSpheres

Other news

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Read more

Upcoming event

Upcoming event

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...

Read more

LinkedIn post ESRR2024

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.